Archive · 25 Jul 2025
Cipla Q1 Profit Rises, Boosted by India and Africa Sales
Cipla, a drug company, made more money in the first three months of 2025 than the same time last year.
Their profit went up by 10%, reaching ₹1,298 crore.
They also made more money from all their sales, about ₹6,957 crore.
The company did well in India, Europe, and Africa.
The company's boss says they will work on growing sales in key markets and focus on important products.
They are also focusing on solving any regulatory issues.
Sales increased in India, Europe and Africa.
However, the sales in North America fell.
Cipla's consolidated profit after tax (PAT) increased by 10% to ₹1,298 crore in Q1 2025.
Total income from operations rose to ₹6,957 crore during the June quarter.
The One-India business grew at 6% year-on-year.
Sales in the Indian market increased to ₹3,070 crore, a 6% rise.
North America sales declined by 7% year-on-year to ₹1,933 crore.
- Who
- Cipla, a drug company.
- What
- Cipla reported a 10% increase in consolidated profit after tax (PAT) to ₹1,298 crore and a rise in total income.
- When
- The report covers the first quarter ended June 30, 2025.
- Where
- The company operates in India, North America, Europe, and Africa.
- Why
- The increase was aided by robust sales growth in India, Europe, and Africa.
- PAT Q1 2025
- ₹1,298 crore
- PAT Q1 2024
- ₹1,178 crore
- Total Income Q1 2025
- ₹6,957 crore
- Total Income Q1 2024
- ₹6,694 crore
- India Sales Growth
- 6%
- North America Sales Decline
- 7%
- Africa Sales Growth
- 14%
- Europe Sales Growth
- 11%